Refine
Year of publication
Document Type
- Preprint (674)
- Article (438)
- Book (2)
- Working Paper (1)
Has Fulltext
- yes (1115)
Is part of the Bibliography
- no (1115)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- SARS-CoV-2 (3)
- pp collisions (3)
- Beauty production (2)
- Charm physics (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Non-structural protein (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- Single electrons (2)
- Solution NMR-spectroscopy (2)
- chemotherapy (2)
- epilepsy (2)
- 3Cs technology (1)
- 900 GeV (1)
- ALICE detector (1)
- ATO (1)
- Abiraterone acetate (1)
- Addison’s disease (1)
- Adipose tissue (1)
- Advanced treatment technologies (1)
- Angiogenesis (1)
- Angiography (1)
- Anti-nuclei (1)
- Atmospheric chemistry (1)
- Atmospheric science (1)
- Bevacizumab (1)
- Bioaccumulation (1)
- Bleeding (1)
- Blood (1)
- Blood plasma (1)
- Boosted Jets (1)
- CNS tumor (1)
- COVID-19 (1)
- COVID19-NMR (1)
- Cell staining (1)
- Centrality Class (1)
- Centrality Selection (1)
- Chromatin and Epigenetics (1)
- Cirrhosis (1)
- Climate change (1)
- Clinical management (1)
- Collective Flow, (1)
- Comparison with QCD (1)
- Concurrent CNS diseases (1)
- Covid19-NMR (1)
- Crispr/Cas (1)
- DUBs (1)
- Deutsch (1)
- Dexamethasone (1)
- Doxorubicin (1)
- E3 Ligase (1)
- Edema (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Emerging contaminants (ECs) (1)
- Endocrine-disrupting compounds (1)
- Environmental fate (1)
- Environmental partitioning (1)
- Environmental risk assessment (1)
- Equilibrium partitioning theory (1)
- FFLU (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Functional outcomes (1)
- Gene Regulation (1)
- Germany (1)
- Gewerkverein der Heimarbeiterinnen Deutschlands für Kleider- und Wäschekonfektion und verwandte Berufe (1900-) (1)
- HBT (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hematoxylin staining (1)
- Histology (1)
- Hodgkin lymphoma (1)
- IAP (1)
- IFN (1)
- IGF (1)
- INR (1)
- Image processing (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- International normalized ratio (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- Lipodystrophy (1)
- Lymph nodes (1)
- Lymphocytes (1)
- Macrodomain (1)
- Material budget (1)
- Metastatic castration-resistant prostate cancer (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiple sclerosis (1)
- NMR spectroscopy (1)
- NOTCH1 (1)
- NVBP (1)
- NanoBRET (1)
- Neural network (1)
- Nuclear modification factor (1)
- Oncology (1)
- PCV (1)
- PROTAC (1)
- PYTHIA (1)
- Paediatric cancer (1)
- Particle and Resonance Production (1)
- Pathologists (1)
- Pb–Pb (1)
- Point-of-care testing (1)
- Portal hypertension (1)
- Portal veins (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Protein drugability (1)
- Proton–proton (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Radiation necrosis (1)
- Radical prostatectomy (1)
- Rapidity Range (1)
- Rare diseases (1)
- Real-world evidence (1)
- Registry (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Risk metrics (risk quotients, toxic units, hazard units) (1)
- SAVI (1)
- SHH (1)
- STING (1)
- Side effect (1)
- Signs and symptoms (1)
- Single muons (1)
- Substantivierter Infinitiv (1)
- Systematic Uncertainty (1)
- TR (1)
- Time Projection Chamber (1)
- Time to treatment failure (1)
- Tools and ressources (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Tschechisch (1)
- Tumour immunology (1)
- Ubiquitin (1)
- Urinary continence (1)
- Urinary incontinence (1)
- Vector Boson Production (1)
- WNT (1)
- Wastewater treatment plant (WWTP) effluents (1)
- White blood cells (1)
- Wide-scope chemical target screening (1)
- Xenon-based gas mixture (1)
- Zweisprachiges Wörterbuch (1)
- accessory proteins (1)
- acute-on-chronic liver failure (ACLF) (1)
- adolescents’ health (1)
- adrenal insuffciency (1)
- adult (1)
- allocation (1)
- angiography (1)
- anticonvulsants (1)
- anxiety (1)
- awake surgery (1)
- bevacizumab (1)
- brain metastases (1)
- cell biology (1)
- cell-free protein synthesis (1)
- cerebral pseudoprogression (1)
- cerebral radiation necrosis (1)
- cerebrospinal fluid (1)
- ceritinib (1)
- child (1)
- clinical practice (1)
- clinical trial (1)
- cortisol (1)
- dE/dx (1)
- decompensated liver cirrhosis (1)
- detector (1)
- diffuse low-grade glioma (1)
- ectosomes (1)
- epileptic encephalopathies (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- fourth (1)
- gRNA library (1)
- genetics and genomics (1)
- genome-wide (1)
- glioma (1)
- graft (1)
- guidelines (1)
- heavy ion experiments (1)
- human (1)
- immune checkpoint inhibitors (ICI) (1)
- immune related adverse events (irAE) (1)
- immunotherapy (1)
- in vivo dosimetry (1)
- inflammation (1)
- intrinsically disordered region (1)
- kidney (1)
- kidney transplantation (1)
- levetiracetam (1)
- loss (1)
- magnetic resonance imaging (1)
- medulloblastoma (1)
- microparticles (1)
- microvesicles (1)
- mindfulness (1)
- minimal information requirements (1)
- monocyte chemotactic protein 1 (MCP-1) (1)
- neurocognition (1)
- neurocognitive outcome (1)
- neurological complication (1)
- neurological side effects (1)
- nitro-fatty acids (1)
- nonstructural proteins (1)
- paediatric nephrology (1)
- palmitoylation (1)
- quality of life (1)
- quark gluon plasma (1)
- radiation dosage (1)
- radiation dosimetry (1)
- radiation protection (1)
- radiotherapy (1)
- randomized (1)
- re-transplantation (1)
- repeated (1)
- reproducibility (1)
- rigor (1)
- risk sport-specific stress (1)
- seizure (1)
- sensation seeking (1)
- spectra (1)
- standardization (1)
- structural proteins (1)
- subgrouping (1)
- survival (1)
- targeted therapy (1)
- temozolomide (1)
- third (1)
- transfer (1)
- transition (1)
- transjugular intrahepatic portosystemic shunt (TIPS) (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1059)
- Frankfurt Institute for Advanced Studies (FIAS) (958)
- Informatik (926)
- Medizin (32)
- Biochemie, Chemie und Pharmazie (4)
- Geowissenschaften (4)
- Geowissenschaften / Geographie (4)
- Georg-Speyer-Haus (3)
- Informatik und Mathematik (3)
- Biochemie und Chemie (2)
A toolbox for the generation of chemical probes for Baculovirus IAP Repeat containing proteins
(2022)
E3 ligases constitute a large and diverse family of proteins that play a central role in regulating protein homeostasis by recruiting substrate proteins via recruitment domains to the proteasomal degradation machinery. Small molecules can either inhibit, modulate or hijack E3 function. The latter class of small molecules led to the development of selective protein degraders, such as PROTACs (PROteolysis TArgeting Chimeras), that recruit protein targets to the ubiquitin system leading to a new class of pharmacologically active drugs and to new therapeutic options. Recent efforts have focused on the E3 family of Baculovirus IAP Repeat (BIR) domains that comprise a structurally conserved but diverse 70 amino acid long protein interaction domain. In the human proteome, 16 BIR domains have been identified, among them promising drug targets such as the Inhibitors of Apoptosis (IAP) family, that typically contain three BIR domains (BIR1, BIR2, and BIR3). To date, this target area lacks assay tools that would allow comprehensive evaluation of inhibitor selectivity. As a consequence, the selectivity of current BIR domain targeting inhibitors is unknown. To this end, we developed assays that allow determination of inhibitor selectivity in vitro as well as in cellulo. Using this toolbox, we have characterized available BIR domain inhibitors. The characterized chemical starting points and selectivity data will be the basis for the generation of new chemical probes for IAP proteins with well-characterized mode of action and provide the basis for future drug discovery efforts and the development of PROTACs and molecular glues.
Background and Aims: Monocyte chemotactic protein-1 (MCP-1) is a potent chemoattractant for monocytes. It is involved in pathogenesis of several inflammatory diseases. Hepatic MCP-1 is a readout of macrophage activation. While inflammation is a major driver of liver disease progression, the origin and role of circulating MCP-1 as a biomarker remains unclear.
Methods: Hepatic CC-chemokine ligand 2 (CCL2) expression and F4/80 staining for Kupffer cells were measured and correlated in a mouse model of chronic liver disease (inhalative CCl4 for 7 weeks). Next, hepatic RNA levels of CCL2 were measured in explanted livers of 39 patients after transplantation and correlated with severity of disease. Changes in MCP-1 were further evaluated in a rat model of experimental cirrhosis and acute-on-chronic liver failure (ACLF). Finally, we analyzed portal and hepatic vein levels of MCP-1 in patients receiving transjugular intrahepatic portosystemic shunt insertion for complications of portal hypertension.
Results: In this mouse model of fibrotic hepatitis, hepatic expression of CCL2 (P = 0.009) and the amount of F4/80 positive cells in the liver (P < 0.001) significantly increased after induction of hepatitis by CCl4 compared to control animals. Moreover, strong correlation of hepatic CCL2 expression and F4/80 positive cells were seen (P = 0.023). Furthermore, in human liver explants, hepatic transcription levels of CCL2 correlated with the MELD score of the patients, and thus disease severity (P = 0.007). The experimental model of ACLF in rats revealed significantly higher levels of MCP-1 plasma (P = 0.028) and correlation of hepatic CCL2 expression (R = 0.69, P = 0.003). Particularly, plasma MCP-1 levels did not correlate with peripheral blood monocyte CCL2 expression. Finally, higher levels of MCP-1 were observed in the hepatic compared to the portal vein (P = 0.01) in patients receiving TIPS. Similarly, a positive correlation of MCP-1 with Child-Pugh score was observed (P = 0.018). Further, in the presence of ACLF, portal and hepatic vein levels of MCP-1 were significantly higher compared to patients without ACLF (both P = 0.039).
Conclusion: Circulating levels of MCP-1 mainly derive from the injured liver and are associated with severity of liver disease. Therefore, liver macrophages contribute significantly to disease progression. Circulating MCP-1 may reflect the extent of hepatic macrophage activation.
In Eurotransplant kidney allocation system (ETKAS), candidates can be considered unlimitedly for repeated re‐transplantation. Data on outcome and benefit are indeterminate. We performed a retrospective 15‐year patient and graft outcome data analysis from 1464 recipients of a third or fourth or higher sequential deceased donor renal transplantation (DDRT) from 42 transplant centers. Repeated re‐DDRT recipients were younger (mean 43.0 vs. 50.2 years) compared to first DDRT recipients. They received grafts with more favorable HLA matches (89.0% vs. 84.5%) but thereby no statistically significant improvement of patient and graft outcome was found as comparatively demonstrated in 1st DDRT. In the multivariate modeling accounting for confounding factors, mortality and graft loss after 3rd and ≥4th DDRT (P < 0.001 each) and death with functioning graft (DwFG) after 3rd DDRT (P = 0.001) were higher as compared to 1st DDRT. The incidence of primary nonfunction (PNF) was also significantly higher in re‐DDRT (12.7%) than in 1st DDRT (7.1%; P < 0.001). Facing organ shortage, increasing waiting time, and considerable mortality on dialysis, we question the current policy of repeated re‐DDRT. The data from this survey propose better HLA matching in first DDRT and second DDRT and careful selection of candidates, especially for ≥4th DDRT.
Understanding how epigenetic variation in non-coding regions is involved in distal gene-expression regulation is an important problem. Regulatory regions can be associated to genes using large-scale datasets of epigenetic and expression data. However, for regions of complex epigenomic signals and enhancers that regulate many genes, it is difficult to understand these associations. We present StitchIt, an approach to dissect epigenetic variation in a gene-specific manner for the detection of regulatory elements (REMs) without relying on peak calls in individual samples. StitchIt segments epigenetic signal tracks over many samples to generate the location and the target genes of a REM simultaneously. We show that this approach leads to a more accurate and refined REM detection compared to standard methods even on heterogeneous datasets, which are challenging to model. Also, StitchIt REMs are highly enriched in experimentally determined chromatin interactions and expression quantitative trait loci. We validated several newly predicted REMs using CRISPR-Cas9 experiments, thereby demonstrating the reliability of StitchIt. StitchIt is able to dissect regulation in superenhancers and predicts thousands of putative REMs that go unnoticed using peak-based approaches suggesting that a large part of the regulome might be uncharted water.
Objectives: Gliomas are often diagnosed due to epileptic seizures as well as neurocognitive deficits. First treatment choice for patients with gliomas in speech-related areas is awake surgery, which aims at maximizing tumor resection while preserving or improving patient’s neurological status. The present study aimed at evaluating neurocognitive functioning and occurrence of epileptic seizures in patients suffering from gliomas located in language-related areas before and after awake surgery as well as during their follow up course of disease.
Materials and Methods: In this prospective study we included patients who underwent awake surgery for glioma in the inferior frontal gyrus, superior temporal gyrus, or anterior temporal lobe. Preoperatively, as well as in the short-term (median 4.1 months, IQR 2.1-6.0) and long-term (median 18.3 months, IQR 12.3-36.6) postoperative course, neurocognitive functioning, neurologic status, the occurrence of epileptic seizures and number of antiepileptic drugs were recorded.
Results: Between 09/2012 and 09/2019, a total of 27 glioma patients, aged 36.1 ± 11.8 years, were included. Tumor resection was complete in 15, subtotal in 6 and partial in 6 patients, respectively. While preoperatively impairment in at least one neurocognitive domain was found in 37.0% of patients, postoperatively, in the short-term, 36.4% of patients presented a significant deterioration in word fluency (p=0.009) and 34.8% of patients in executive functions (p=0.049). Over the long-term, scores improved to preoperative baseline levels. The number of patients with mood disturbances significantly declined from 66.7% to 34.8% after surgery (p=0.03). Regarding seizures, these were present in 18 (66.7%) patients prior to surgery. Postoperatively, 22 (81.5%) patients were treated with antiepileptic drugs with all patients presenting seizure-freedom.
Conclusions: In patients suffering from gliomas in eloquent areas, the combination of awake surgery, regular neurocognitive assessment - considering individual patients´ functional outcome and rehabilitation needs – and the individual adjustment of antiepileptic therapy results in excellent patient outcome in the long-term course.